top of page
AAO 2026: RETINA DRUG DELIVERY & NEW TARGETS SHOWCASE
Moderators: Allen C. Ho, MD, Retina Program Director; Rachel Huckfeldt, MD, PhD ; Mark Humayun, MD, PhD; and John Trein, MD
Rooms: 252-254
Start | Company | Presenter |
|---|---|---|
1:00 PM | Introduction | |
1:01 PM | Nanoscope Therapeutics | Samuel Barone, MD, Chief Medical Officer |
1:06 PM | AAVantgarde | Natalia Misciattelli, PhD, CEO |
1:11 PM | Ocugen | Shankar Musunuri, PhD, MBA, CEO & Co-Founder |
1:16 PM | Discussion | |
1:23 PM | Adverum Biotechnologies | Star Seyedkazemi, PharmD, Chief Development Officer |
1:28 PM | Kriya Therapeutics | Shankar Ramaswamy, MD, Co-Founder & CEO |
1:33 PM | Discussion | |
1:38 PM | Optigo Biotherapeutics | Houman Hemmati, MD, PhD, Co-founder & Chief Medical Officer |
1:43 PM | Valitor | Greg Kunst, MBA, CEO |
1:48 PM | Re-Vana Therapeutics | Michael J. O'Rourke, CEO |
1:53 PM | Discussion | |
2:00 PM | Yale University FerRx Bio | Lucian V. Del Priore, MD, PhD, Chair, Ophthalmology and Visual Science Dept, Yale School of Medicine |
2:05 PM | MingMed Biotechnology | Fred Ouyang, PhD, MBA, Chief Technical Officer |
2:10 PM | Discussion | |
2:15 PM | InGel Therapeutics | Pierre Dromel, PhD, CEO/CTO |
2:20 PM | Neurotech Pharmaceuticals, Inc. | Rich Small, CEO |
2:25 PM | Discussion | |
2:30 PM | Conclusion | |
2:31 PM | End of Session |
Anchor 1
bottom of page